12-Month Target: $9.00

24-month target $5.00

Rarely in biotech do we see a situation where an investor can simply perform their own due diligence and be on the right side of the trade without needing to be a scientist. In the case of AveXis (NASDAQ:AVXS), all you need is a healthy dose of skepticism, willingness to do the research, and a bit of empathy to reveal that there’s nothing here beyond a glorified stock promotion. It will soon trade in the single digits.

The hopeful story of a cure for terminally ill babies is powerful enough to bring forth the worst of Wall Street’s greed, which has the power to sell this story to investors despite the absence of real clinical data. If it wasn’t for the horrendously warped way the US pharma market prices its drugs, AveXis could not even have completed its IPO.

Given the news flow since IPO, this stock should be trading below its IPO price of $20 now. As a high-credibility competitor nears FDA approval, as much as 3 years ahead of AveXis, its window of opportunity may have already closed shut.

Citron Exposes the Clinical Study Cyberdyne Does Not Want You To See- We Reaffirm Price Target 300¥

In this recent report, Citron exposes the clinical study conducted by Cyberdyne that shows that patients who use the HAL have minimal better outcomes than those who use a simple hospital hoist system. The clinical report also details that over 65% of people who use HAL experience some adverse events. Citron believes this is the reason why the company has not submitted anything to the FDA and more importantly the reason why the HAL has not achieved any meaningful sales in either Japan or Europe. We believe this clinical study to be the smoking gun on why Cyberdyne is on its way to 300¥ per share.